Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

FTSE 250 retreats as Brexit hangs in balance; GSK dips on vaccine delay

Published 11/12/2020, 09:11
Updated 11/12/2020, 09:12
© Reuters.

© Reuters.

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)
* FTSE 100 up 0.1%, FTSE 250 off 0.2%

Dec 11 (Reuters) - London's mid-cap index slipped on Friday
on fears of a tumultuous no-deal Brexit in three weeks, while
GlaxoSmithKline dipped after announcing a delay in its efforts
to develop a COVID-19 vaccine.
The drugmaker GSK.L dropped 0.2% after it said the
experimental vaccine it was developing with France's Sanofi
SASY.PA showed an insufficient immune response in clinical
trials and it now hoped to come up with a more effective vaccine
by 2021 end. Sanofi's Paris-listed shares were down 2%.
The domestically-focussed FTSE 250 .FTMC slipped 0.2%,
deepening losses of more than 2% this week, as Prime Minister
Boris Johnson said there was "a strong possibility" Britain and
the European Union would fail to strike a new trade
deal. The blue-chip FTSE 100 .FTSE shed 0.1%, with declines in
consumer staples and mining stocks more than offsetting a jump
in financial stocks.
Banks .FTNMX8350 , the worst-performing FTSE sector this
week, rose 0.7% as the Bank of England said they could resume
paying some dividends and bonuses.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.